Repligen Corporation (NASDAQ:RGEN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUSĀ® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. “

RGEN has been the topic of a number of other reports. BidaskClub upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. William Blair began coverage on shares of Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating for the company. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Finally, Stephens reissued an “overweight” rating and issued a $50.00 price objective on shares of Repligen Corporation in a research report on Tuesday, September 26th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $45.40.

Repligen Corporation (NASDAQ:RGEN) opened at 37.47 on Wednesday. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The company has a market cap of $1.40 billion, a PE ratio of 73.33 and a beta of 1.18. The firm has a 50 day moving average price of $41.51 and a 200 day moving average price of $39.68.

Repligen Corporation (NASDAQ:RGEN) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period last year, the business posted $0.16 earnings per share. On average, analysts anticipate that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Repligen Corporation (RGEN) Cut to “Hold” at Zacks Investment Research” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/repligen-corporation-rgen-cut-to-hold-at-zacks-investment-research-2.html.

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Quantbot Technologies LP bought a new stake in shares of Repligen Corporation in the 2nd quarter valued at $120,000. Ameritas Investment Partners Inc. acquired a new position in shares of Repligen Corporation during the 1st quarter valued at $103,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Repligen Corporation during the 2nd quarter valued at $123,000. Victory Capital Management Inc. lifted its position in shares of Repligen Corporation by 76.6% during the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 1,475 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Repligen Corporation by 31.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 908 shares during the period. 97.91% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Get a free copy of the Zacks research report on Repligen Corporation (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.